However, anecdotal reports have described remarkable responses in salivary tumors when genetic aberrations and therapies were matched: trastuzumab and lapatinib for Her2-aberrant salivary tumors [23] or mTOR inhibitors for PIK3CA-aberrant neoplasms [24]. Here, PIK3CA is linked to neoplasm.